Your browser doesn't support javascript.
loading
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group.
Luoma, Sini; Anttila, Pekka; Säily, Marjaana; Lundan, Tuija; Heiskanen, Jouni; Siitonen, Timo; Kakko, Sakari; Putkonen, Mervi; Ollikainen, Hanna; Terävä, Venla; Sankelo, Marja; Partanen, Anu; Launonen, Kirsi; Räsänen, Anu; Sikiö, Anu; Suominen, Merja; Bazia, Piotr; Kananen, Kristiina; Lievonen, Juha; Selander, Tuomas; Pelliniemi, Tarja-Terttu; Ilveskero, Sorella; Huotari, Virva; Mäntymaa, Pentti; Tienhaara, Anri; Jantunen, Esa; Silvennoinen, Raija.
  • Luoma S; Comprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. sini.luoma@hus.fi.
  • Anttila P; Comprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Säily M; Hematology-Oncology Unit, Oulu University Hospital, Oulu, Finland.
  • Lundan T; Department of Clinical Chemistry and TYKSLAB, University of Turku and Turku University Hospital, Turku, Finland.
  • Heiskanen J; Comprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Siitonen T; Hematology-Oncology Unit, Oulu University Hospital, Oulu, Finland.
  • Kakko S; Hematology-Oncology Unit, Oulu University Hospital, Oulu, Finland.
  • Putkonen M; Hematology Unit, Turku University Hospital, Turku, Finland.
  • Ollikainen H; Department of Medicine, Satakunta Central Hospital, Pori, Finland.
  • Terävä V; Hematology Unit, Tampere University Hospital, Tampere, Finland.
  • Sankelo M; Hematology Unit, Tampere University Hospital, Tampere, Finland.
  • Partanen A; Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
  • Launonen K; Department of Medicine, Mikkeli Central Hospital, Mikkeli, Finland.
  • Räsänen A; Hematology-Oncology Unit, Oulu University Hospital, Oulu, Finland.
  • Sikiö A; Department of Medicine, Länsi-Pohja Central Hospital, Kemi, Finland.
  • Suominen M; Department of Medicine, Kymenlaakso Central Hospital, Kotka, Finland.
  • Bazia P; Department of Medicine, Central Finland Central Hospital, Jyväskylä, Finland.
  • Kananen K; Department of Medicine, Kanta-Häme Central Hospital, Hämeenlinna, Finland.
  • Lievonen J; Department of Medicine, Kainuu Central Hospital, Kajaani, Finland.
  • Selander T; Department of Medicine, Kainuu Central Hospital, Kajaani, Finland.
  • Pelliniemi TT; Comprehensive Cancer Center, Department of Hematology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Ilveskero S; Science Service Center, Kuopio University Hospital, Kuopio, Finland.
  • Huotari V; Fimlab Laboratories Ltd., Tampere, Finland.
  • Mäntymaa P; HUSLAB Helsinki University Hospital, Helsinki, Finland.
  • Tienhaara A; Fimlab Laboratories Ltd., Tampere, Finland.
  • Jantunen E; NordLab Oulu, Oulu University Hospital, Oulu, Finland.
  • Silvennoinen R; Laboratory of Eastern Finland, Kuopio University Hospital, Kuopio, Finland.
Ann Hematol ; 98(12): 2781-2792, 2019 Dec.
Article en En | MEDLINE | ID: mdl-31673775

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre / Quimioterapia de Mantención / Lenalidomida / Mieloma Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País como asunto: Europa Idioma: En Año: 2019 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre / Quimioterapia de Mantención / Lenalidomida / Mieloma Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País como asunto: Europa Idioma: En Año: 2019 Tipo del documento: Article